Completely Resected Non-Small Cell Lung Cancer: Reconsidering Prognostic Value and Significance of N2 Metastases Marc Riquet, MD, PhD, Patrick Bagan,

Slides:

Advertisements

Similar presentations

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Advertisements

Number of Mediastinal Lymph Nodes in Non-Small Cell Lung Cancer: A Gaussian Curve, Not a Prognostic Factor Marc Riquet, MD, PhD, Antoine Legras, MD,

Jeffrey L. Port, MD, Robert J. Korst, MD, Paul C. Lee, MD, Amanda L

Complete Thoracic Mediastinal Lymphadenectomy Leads to a Higher Rate of Pathologically Proven N2 Disease in Patients With Non-Small Cell Lung Cancer

Number of Lymph Nodes and Metastatic Lymph Node Ratio Are Associated With Survival in Lung Cancer Chukwumere E. Nwogu, MD, Adrienne Groman, MA, Daniel.

History of Multiple Previous Malignancies Should Not Be a Contraindication to the Surgical Resection of Lung Cancer Pierre-Benoit Pagès, MD, Pierre Mordant,

Long-Term Survival of Patients With pN2 Lung Cancer According to the Pattern of Lymphatic Spread Antoine Legras, MD, Pierre Mordant, MD, PhD, Alex Arame,

Preoperative Serum Fibrinogen Level Predicts Postoperative Pulmonary Complications After Lung Cancer Resection Suk-Won Song, MD, Hyun-Sung Lee, MD, Moon.

Melanie Subramanian, MD, Timothy McMurry, PhD, Bryan F

Is the Rate of Pneumonectomy Higher in Right Middle Lobe Lung Cancer Than in Other Right-Sided Locations? Caroline Rivera, MD, Pierre Mordant, MD, PhD,

Missed Intrapulmonary Lymph Node Metastasis and Survival After Resection of Non- Small Cell Lung Cancer Matthew P. Smeltzer, PhD, Nicholas Faris, MDiv,

Tumor Necrosis as a Prognostic Factor for Stage IA Non-Small Cell Lung Cancer Seong Yong Park, MD, Hyun-Sung Lee, MD, PhD, Hee-Jin Jang, MD, Geon Kook.

Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD

Clinical Prognosis of Superior Versus Basal Segment Stage I Non-Small Cell Lung Cancer Yoshinori Handa, MD, Yasuhiro Tsutani, MD, PhD, Norifumi Tsubokawa,

Number of Mediastinal Lymph Nodes in Non-Small Cell Lung Cancer: A Gaussian Curve, Not a Prognostic Factor Marc Riquet, MD, PhD, Antoine Legras, MD,

Prognostic Factors Associated With Interventional Bronchoscopy in Lung Cancer Nicolas Guibert, MD, Julien Mazieres, MD, PhD, Benoît Lepage, MD, Gavin.

Prognostic Factors and Analysis of Microsatellite Instability in Resected Pulmonary Metastases From Colorectal Carcinoma Giulio Melloni, MD, Claudio.

Morbidity, Survival, and Site of Recurrence After Mediastinal Lymph-Node Dissection Versus Systematic Sampling After Complete Resection for Non-Small.

Osteopontin Combined With CD44v6, a Novel Prognostic Biomarker in Non-Small Cell Lung Cancer Undergoing Curative Resection Bing-sheng Sun, MD, PhD, Yue.

Non-Small Cell Lung Cancer Resection in Lymphoma Patients

Lymph Node Evaluation Achieved by Open Lobectomy Compared With Thoracoscopic Lobectomy for N0 Lung Cancer Robert E. Merritt, MD, Chuong D. Hoang, MD,

Risk Factors for Lymph Node Metastases and Prognosticators of Survival in Patients Undergoing Pulmonary Metastasectomy for Colorectal Cancer Servet Bölükbas,

Prognostic Predictors in Non-Small Cell Lung Cancer Patients Undergoing Intentional Segmentectomy Terumoto Koike, MD, PhD, Teruaki Koike, MD, PhD, Yasushi.

Brendon M. Stiles, MD, Farooq Mirza, MD, Jeffrey L. Port, MD, Paul C

The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao,

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Michelle C. Ellis, MD, Brian S. Diggs, PhD, John T. Vetto, MD, Paul H

Lobe-specific extent of systematic lymph node dissection for non–small cell lung carcinomas according to a retrospective study of metastasis and prognosis

Philip W. Smith, MD, Hongkun Wang, PhD, Leo M. Gazoni, MD, K

Readmission to Intensive Care Unit After Initial Recovery From Major Thoracic Oncology Surgery Suk-Won Song, MD, Hyun-Sung Lee, MD, PhD, Jae-Hyun Kim,

Positron Emission Tomography-Computed Tomography for Postoperative Surveillance in Non-Small Cell Lung Cancer Se Hoon Choi, MD, Young Tae Kim, MD, PhD,

Asad A. Shah, MD, Mathias Worni, MD, MHS, Christopher R

Bilobectomy for Lung Cancer: Analysis of Indications, Postoperative Results, and Long- Term Outcomes Domenico Galetta, MD, PhD, Piergiorgio Solli, MD,

Use of Amiodarone After Major Lung Resection

Elliot Wakeam, MD, MPH, James P. Byrne, MD, Gail E

Abel Gómez-Caro, MD, Pedro Arguis, MD The Annals of Thoracic Surgery

Prognostic Significance of Surgical-Pathologic N1 Lymph Node Involvement in Non- Small Cell Lung Cancer Adalet Demir, MD, Akif Turna, MD, PhD, FETCS,

Smoking Status as a Prognostic Factor in Patients with Stage I Pulmonary Adenocarcinoma Ichiro Yoshino, MD, PhD, Daigo Kawano, MD, Taro Oba, MD, Koji.

Recurrence and Survival After Segmentectomy in Patients With Prior Lung Resection for Early-Stage Non-Small Cell Lung Cancer Lisa M. Brown, MD, Brian.

The Prognostic Value of the Number of Negative Lymph Nodes in Esophageal Cancer Patients After Transthoracic Resection Po-Kuei Hsu, MD, Chien-Sheng Huang,

Differences in Patterns of Recurrence in Early-Stage Versus Locally Advanced Non- Small Cell Lung Cancer Feiran Lou, MD, MS, Camelia S. Sima, MD, MS,

Surgical Therapy for Bilateral Multiple Primary Lung Cancer

Valerie W Rusch, MD, Ennapadam S Venkatraman, PhD

Intrathoracic Lymph Node Metastases From Extrathoracic Carcinoma: The Place for Surgery Marc Riquet, MD, Pascal Berna, MD, Emmanuel Brian, MD, Alain.

Renal Cell Carcinoma Lung Metastases Surgery: Pathologic Findings and Prognostic Factors Jalal Assouad, MD, Boriana Petkova, MD, Pascal Berna, MD, Antoine.

Sublobar Resection Provides an Equivalent Survival After Lobectomy in Elderly Patients With Early Lung Cancer Jiro Okami, MD, PhD, Yuri Ito, PhD, Masahiko.

Prognostic significance of surgical-pathologic N1 disease in non-small cell carcinoma of the lung Marc Riquet, MD, Dominique Manac’h, MD, Françoise Le.

Lymph Node Assessment and Impact on Survival in Video-Assisted Thoracoscopic Lobectomy or Segmentectomy Haiyu Zhou, MD, Luis F. Tapias, MD, Henning A.

Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis Shun-ichi Watanabe, MD, Kenji Suzuki,

Prognostic Differences in Subgroups of Patients With Surgically Resected T3 Non-Small Cell Lung Cancer Jae Hyun Jeon, MD, Moon Soo Kim, MD, Duk Hwan.

Surgical Treatment for Limited-Stage Primary Small Cell Cancer of the Esophagus Dongrong Situ, MD, Yongbin Lin, MD, PhD, Hao Long, MD, PhD, Lanjun Zhang,

Number of Metastatic Lymph Nodes in Resected Non–Small Cell Lung Cancer Predicts Patient Survival Jin Gu Lee, MD, Chang Young Lee, MD, In Kyu Park, MD,

Prognosis of Resected Non-Small Cell Lung Cancer Patients with Intrapulmonary Metastases Kanji Nagai, MD, Yasunori Sohara, MD, Ryosuke Tsuchiya, MD,

James D Luketich, Michael E Burt The Annals of Thoracic Surgery

Shared Decision Making and Effective Risk Communication in the High-Risk Patient With Operable Stage I Non-Small Cell Lung Cancer Pamela Samson, MD,

Prognostic Factors and Surgical Indications of Pulmonary Epithelioid Hemangioendothelioma: A Review of the Literature Patrick Bagan, MD, Mohammed Hassan,

Prognostic Heterogeneity in Multilevel N2 Non-Small Cell Lung Cancer Patients: Importance of Lymphadenopathy and Occult Intrapulmonary Metastases Yukinori.

Immediate and Long-Term Survival After Surgery for Lung Cancer in Heart Transplant Recipients Patrick Bagan, MD, Jalal Assouad, MD, Pascal Berna, MD,

Pneumonectomy After Chemoradiation Therapy for Non-Small Cell Lung Cancer: Does “Side” Really Matter? Anthony W. Kim, MD, L. Penfield Faber, MD, William.

Effect of Formalin Fixation on Tumor Size Determination in Stage I Non-Small Cell Lung Cancer Po-Kuei Hsu, MD, Hsu-Chih Huang, MD, Chih-Cheng Hsieh,

Clinical Outcome After Pulmonary Resection for Lung Cancer Patients on Hemodialysis Toshiro Obuchi, MD, Wakako Hamanaka, MD, Yasuhiro Yoshida, MD, Jun.

Survival and Outcomes of Pulmonary Resection for Non-Small Cell Lung Cancer in the Elderly: A Nested Case-Control Study Robert J. Cerfolio, MD, Ayesha.

Mark I. Block, MD The Annals of Thoracic Surgery

Lobectomy Versus Limited Resection in T1N0 Lung Cancer

Peripheral intrapulmonary lymph node metastases of non-small-cell lung cancer Souheil Boubia, MD, Françoise Lepimpec Barthes, MD, Claire Danel, MD, Marc.

Domenico Galetta, MD, PhD, Lorenzo Spaggiari, MD, PhD

Prognostic factors for survival after pulmonary resection of metastatic renal cell carcinoma Joachim Pfannschmidt, MD, Hans Hoffmann, MD, PhD, Thomas.

Early Surgical Results After Pneumonectomy for Non-Small Cell Lung Cancer are not Affected by Preoperative Radiotherapy and Chemotherapy Tomas Gudbjartsson,

Lung Cancer Invading the Pericardium: Quantum of Lymph Nodes

Induction Therapy Followed by Surgery for T3-T4/N0 Non-Small Cell Lung Cancer: Long-Term Results Filippo Lococo, MD, Alfredo Cesario, MD, Stefano Margaritora,

Presentation transcript:

Completely Resected Non-Small Cell Lung Cancer: Reconsidering Prognostic Value and Significance of N2 Metastases Marc Riquet, MD, PhD, Patrick Bagan, PMD, Françoise Le Pimpec Barthes, MD, Eugeniu Banu, MD, Florian Scotte, MD, Christophe Foucault, MD, Antoine Dujon, MD, Claire Danel, MD The Annals of Thoracic Surgery Volume 84, Issue 6, Pages 1818-1824 (December 2007) DOI: 10.1016/j.athoracsur.2007.07.015 Copyright © 2007 The Society of Thoracic Surgeons Terms and Conditions

Fig 1 Five-year and 10-year survival rates of single N2 patients (curve 1) and multiple N2 patients (curve 2). Survival difference were similar when postoperative and cancer-unrelated deaths were excluded: single N2 (n = 305), 32.2% (median, 28 months); multiple N2 (n = 167), 19% (median, 17 months; p = 0.00008.) The Annals of Thoracic Surgery 2007 84, 1818-1824DOI: (10.1016/j.athoracsur.2007.07.015) Copyright © 2007 The Society of Thoracic Surgeons Terms and Conditions

Fig 2 Five-year survival rates according to the size of lymph nodes. Nonbulky N2 (curve 2) demonstrated the best prognosis with a 5-year overall survival of 34% (median, 28 months). Micrometastases (curve 1) and bulky metastases (curve 3) demonstrated similar 5-year survival rates: 21.4% (median, 23 months) and 23% (median, 23 months), respectively. Difference between curve 2 and 3 was significant (p = 0.026). The Annals of Thoracic Surgery 2007 84, 1818-1824DOI: (10.1016/j.athoracsur.2007.07.015) Copyright © 2007 The Society of Thoracic Surgeons Terms and Conditions

Fig 3 Five-year survival rates according to the size of lymph node metastases when cancer-unrelated causes of death (postoperative and known medical causes) were excluded. Differences between the three subgroups were not significant: 5-year overall survival (median) were 24.4% (24 months), 40.1% (35 months), and 26.1% (24 months), respectively; the difference between G2 and G3 was significant (p = 0.03). The Annals of Thoracic Surgery 2007 84, 1818-1824DOI: (10.1016/j.athoracsur.2007.07.015) Copyright © 2007 The Society of Thoracic Surgeons Terms and Conditions

Fig 4 Five-year survival rates when only one lymph node was metastatic within the station: survival of micrometastases group (curve 1, 5-year overall survival, 16.6%; median, 23 months) was poorer (p = 0.02), whereas significance between the nonbulky metastases (curve 2; 5-year, 32.5%; median, 30 months) and bulky (curve 3; 5-year, 27.6%; median 23 months) was not significant (p = 0.12). The Annals of Thoracic Surgery 2007 84, 1818-1824DOI: (10.1016/j.athoracsur.2007.07.015) Copyright © 2007 The Society of Thoracic Surgeons Terms and Conditions